Ottimo Pharma
Sandwich
About Ottimo Pharma
Ottimo Pharma focuses on creating pioneering cancer treatments for solid tumors, specifically through its lead program, Jankistomig, a bi-functional antibody targeting immune checkpoints and angiogenesis. The company aims to enhance treatment outcomes and alleviate healthcare burdens by advancing this dual-pathway approach.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $140.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2024)
- Website: ottimopharma.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ottimo-pharma-54834 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.